EUVIMEDEUVIMED entdecken
Open Access

Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US

Nora C Burdis, Miranda C Bradford, Sonya L Heltshe, Tijana Milinic, Oliver J McElvaney, Erika D Lease, Christopher H Goss, Siddhartha G Kapnadak, Brandon L Guthrie, Kathleen J Ramos

Journal of Cystic Fibrosis · 2025-09 · 24 (5) · 929-934

DOI: 10.1016/j.jcf.2025.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-09. Verfasst von Nora C Burdis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, United States. Hauptthemen laut MEDLINE: Cystic Fibrosis, Lung Transplantation, Aminophenols, Quinolones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NINR NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved pulmonary and extrapulmonary manifestations of cystic fibrosis (CF). ETI clinical trials excluded lung transplant (LTx) recipients and current post-transplant prescribing practices are not evidence-based. We sought to identify the prevalence of new ETI prescriptions among CF LTx recipients in the United States (U.S.) and factors associated with ETI prescription after LTx. METHODS: We performed a retrospective cross-sectional study of LTx recipients through December 2022 using the Cystic Fibrosis Foundation Patient Registry. Recipients were alive as of October 2019, had an ETI-eligible genotype, and were not prescribed ETI before LTx. Logistic regression was used to assess factors associated with ETI prescription. CF Center prescribing patterns were categorized based on the proportion of LTx recipients who were prescribed ETI after LTx at each center. RESULTS: Overall, 488/1666 (29.3 %) of patients were prescribed ETI after LTx. The presence of sinus disease (OR 2.12, 95 % CI 1.51-2.99) and BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisLung TransplantationAminophenolsQuinolonesBenzodioxolesChloride Channel AgonistsPractice Patterns, Physicians'IndolesPyrazolesPyridinesPyrrolidinesDrug PrescriptionsHumansMaleFemaleCross-Sectional StudiesRetrospective StudiesUnited StatesAdultDrug CombinationsRegistries

Stichwörter der Autor:innen

CFTR modulatorCystic fibrosisElexacaftorIvacaftorLung transplantationTezacaftor

Substanzen

AminophenolsQuinolonesBenzodioxolesDrug CombinationsChloride Channel AgonistsIndolesPyrazolesPyridinesPyrrolidinesivacaftor

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, United States.
  • Seattle Children's Research Institute, Biostatics Epidemiology and Analytics in Research (BEAR) Core, Seattle, WA, United States.
  • Division of Pulmonary and Allergy, Department of Pediatrics, University of Washington, Seattle WA, United States; CFF TDNCC Seattle Children's Research Institute, Seattle, WA, United States.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, United States; Division of Pulmonary and Allergy, Department of Pediatrics, University of Washingto…
  • School of Public Health, Department of Global Health, University of Washington, Seattle, WA, United States.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, United States; CFF TDNCC Seattle Children's Research Institute, Seattle, WA, United States. Electro…

Förderung

  • NIDDK NIH HHS
  • NINR NIH HHS
  • NHLBI NIH HHS
  • National Institute of Nursing Research
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases

Zitieren

APA

Burdis, N. C., Bradford, M. C., Heltshe, S. L., Milinic, T., McElvaney, O. J., Lease, E. D., Goss, C. H., Kapnadak, S. G., Guthrie, B. L., & Ramos, K. J. (2025). Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US. Journal of Cystic Fibrosis, 24(5), 929-934. https://doi.org/10.1016/j.jcf.2025.06.005

Vancouver

Burdis NC, Bradford MC, Heltshe SL, Milinic T, McElvaney OJ, Lease ED, et al. Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US. Journal of Cystic Fibrosis. 2025;24(5):929-934. doi:10.1016/j.jcf.2025.06.005

BibTeX
@article{Burdis2025,
  author = {Burdis, Nora C and Bradford, Miranda C and Heltshe, Sonya L and Milinic, Tijana and McElvaney, Oliver J and Lease, Erika D and Goss, Christopher H and Kapnadak, Siddhartha G and Guthrie, Brandon L and Ramos, Kathleen J},
  title = {Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {5},
  pages = {929--934},
  doi = {10.1016/j.jcf.2025.06.005}
}
Kostenlos starten →